ARTICLES BY SUBIR BASAK

  • What Can Biosimilar Developers Learn From The 1990s Biopharma Industry?
    What Can Biosimilar Developers Learn From The 1990s Biopharma Industry?

    This article highlights some of the early biologics industry decisions and thought processes and the subsequent actions and opportunities biosimilars create for the pharma industry.

  • Tips For Success In the Indian Biosimilar Market
    Tips For Success In the Indian Biosimilar Market

    In part 3 of this three-part series, Basak discusses the challenges of raising funds to develop and commercialize biosimilars in India, provides advice to biosimilar companies looking to enter the market, and shares his vision of the future for biosimilars in India.

  • India Map
    How India Cultivated A Thriving Biosimilar Ecosystem

    Although the biosimilar space is still growing and evolving in the U.S., it is comparatively well-established in India. According to the Generics and Biosimilars Initiative (GaBI), the first “similar biologic” was approved and marketed in India in 2000 — some 15 years before the U.S. approved its first biosimilar. 

subir_basak

Subir Basak

Subir K. Basak is a management consultant and executive advisor to the biotech, pharmaceutical, and medical device industry, with an avid interest in innovation, global strategy and operations, entrepreneurship, and finance. He helped launch the first biosimilar product in the EU and several products into various emerging markets including Latin America, Southeast Asia, Europe, and the Middle East. Basak holds an MBA from the Kellogg School of Management, an M.S. and Ph.D. from Purdue University, and a B.E. from the Indian Institute of Technology (IIT) Roorkee. He was a Merck Fellow and received advanced management education from the Wharton School at the University of Pennsylvania. You can reach him at subir.basak@gmail.com or connect with him on LinkedIn.